Sep 8, 2026, 2:37 PMBiopharma Clinical Trials
Novartis Cholesterol Trial Failure Sparks Broad Biopharma Selloff
Novartis's failed cholesterol-drug trial triggered a broad biopharma selloff, challenging hopes that lowering Lp(a) can prevent fatal heart events in patients.
Listen to this briefingAudio briefing
Summary
MarketWatch reported on September 8, 2026, that a Novartis cholesterol-drug trial failed, triggering a broad selloff in biopharma stocks. Novartis and several other drugmakers have bet that lowering Lp(a) will reduce the risk of cardiovascular events that can be fatal.
Only a short feed summary was available. It did not identify the drug, trial phase, endpoints, efficacy or safety results, affected companies, share-price moves, or next steps, limiting assessment of the setback.
Positives
- Several drugmakers are pursuing Lp(a) lowering, showing the target has attracted development interest beyond Novartis.
- The programs seek to reduce cardiovascular events that can be fatal, giving the research a clinically significant objective.
- The failed trial provides a relevant data point for drugmakers pursuing the same Lp(a) hypothesis.
Risks & concerns
- Novartis's cholesterol-drug trial failed, weakening confidence in its approach to lowering Lp(a).
- The result triggered a broad biopharma stock selloff, indicating concern extended beyond Novartis.
- Several drugmakers have placed bets on the same Lp(a) strategy, exposing peers to read-across risk.
- The feed omitted the drug, trial design, results, affected stocks, market declines, and next steps.
Primary sourceMarketWatch.com - Top Storieshttps://www.marketwatch.com/story/novartiss-failed-trial-for-cholesterol-drug-leads-to-broad-biopharma-selloff-2d487746?mod=mw_rss_topstories
Read full article
